MedTrace Logo

The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT

NCT05112523 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-11-09

No results posted yet for this study

Summary

Investigators performed the Genetron Uro V1 test on the urine of patients before secondary TURBT and compared it with the final pathological results. To analyze the performance of the Genetron Uro V1 method in a study to predict the need for secondary TURBT in high-risk NMIBC patients and the correlation with patient's RFS and OS.

Conditions

Sponsors & Collaborators

  • Hangzhou Jichenjunchuang Medical Laboratory Company

    collaborator UNKNOWN

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Qiang Lv, MD，PHD · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-20
Primary Completion
2022-08-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05112523 on ClinicalTrials.gov